Drug Combination Details
General Information of the Combination (ID: C36772) | |||||
---|---|---|---|---|---|
Name | Hesperetin NP Info | + | Cisplatin Drug Info | ||
Structure | + | ||||
Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | AIFM1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PTEN | Molecule Info |
Pathway MAP
|
||
In-vitro Model | GES-1 | CVCL_EQ22 | Healthy | Homo sapiens | ||
HGC-27 | CVCL_1279 | Gastric carcinoma | Homo sapiens | |||
SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | |||
MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | |||
HGC-27/DDP | Gastric carcinoma | Homo sapiens | ||||
In-vivo Model | HGC-27 cells were suspended in 100 ul of PBS, and then implanted into the dorsal area, subcutaneously, of male BALB/c nude mice. | |||||
Experimental
Result(s) |
Hesperetin could inhibit the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling pathway and induce the mitochondrial pathway via upregulating PTEN expression, thereby significantly enhancing DDP's anti-tumor effect on GC. |
References | ||||
---|---|---|---|---|
Reference 1 | Hesperetin Promotes Cisplatin-Induced Apoptosis of Gastric Cancer In Vitro and In Vivo by Upregulating PTEN Expression. Front Pharmacol. 2020 Aug 27;11:1326. |